Il vaccino terapeutico italiano anti-Aids, in fase di sperimentazione, riporta verso la normalità le funzioni immunitarie dei malati. Un risultato più che promettente, “entusiasmante” lo definisce Barbara Ensoli, del Centro nazionale AIDS dell’Istituto superiore di Sanità, che sta sviluppando il vaccino.
Uno studio pubblicato magazine PlosOne , which reports the results of the interim analysis of phase II clinical trial, shows that in 87 patients after 48 weeks significantly improves the immune system already compromised by the virus, thanks to the combined vaccine Tat with antiretroviral therapy.
'improve their quality of life - says Ensoli - because even if the treatment stops the virus fail to block a range of other disorders that continue to be, from cardiovascular to those in the brain, up to premature aging, with people 40 years shows that 70. " A perverse effect of Tat, the real "engine" of the HIV virus, which continues to act even while receiving antiretroviral therapy and compromise the immune system. Just Tat acts against the vaccine, triggering an immune response lasting, ultimately making the virus a car without engine, and defuse the destructive action.
"This vaccine - says Ensoli - get where drugs do not arrive. Block immunoattivazione, increased B cells, immune cells gather capabilities, there is in fact a return to equilibrium in patients already receiving an effective drug therapy. "
"These results - highlights the ISS President Enrico Garaci - dimostrano che valeva la pena di esplorare le potenzialità del vaccino Tat. Il miglioramento dei parametri immunologici nei pazienti vaccinati trattati con terapia antiretrovirale rappresenta una tappa importante, e non ci fermiamo qui». I passi successivi sono ancora più ambiziosi: valutare l’effetto del vaccino in pazienti sintomatici, per bloccare la malattia, e poi valutare l’effetto preventivo del vaccino, ossia su pazienti sani. «Il meccanismo della Tat è sempre quello - conferma Ensoli - e noi speriamo che il vaccino funzioni anche per le altre indicazioni. Finora abbiamo ottenuto risultati superiori alle nostre aspettative, e molto rapidi».
L’iter di sperimentazione del vaccino Italian treatment started 15 years ago, the clinical phase I started in 2003, Phase II in 2008 and has yet to finish. The problem, however, said Ensoli, time is money: "We no longer have funds to complete Phase II."
beginning of the trial were spent around 20 million euro, against the Ministry of Health and Iss, "but the figure was 20 times higher," highlights Garaci, to test whether the vaccine had been an private rather than public bodies. Now the ISS holds 10 patents which, when it comes to produce the vaccine will also be sold to private companies. "Our goal is to treat patients and we have no foreclosure on transparent partnerships with the private sector, "concludes Ensoli.
Uno studio pubblicato magazine PlosOne , which reports the results of the interim analysis of phase II clinical trial, shows that in 87 patients after 48 weeks significantly improves the immune system already compromised by the virus, thanks to the combined vaccine Tat with antiretroviral therapy.
'improve their quality of life - says Ensoli - because even if the treatment stops the virus fail to block a range of other disorders that continue to be, from cardiovascular to those in the brain, up to premature aging, with people 40 years shows that 70. " A perverse effect of Tat, the real "engine" of the HIV virus, which continues to act even while receiving antiretroviral therapy and compromise the immune system. Just Tat acts against the vaccine, triggering an immune response lasting, ultimately making the virus a car without engine, and defuse the destructive action.
"This vaccine - says Ensoli - get where drugs do not arrive. Block immunoattivazione, increased B cells, immune cells gather capabilities, there is in fact a return to equilibrium in patients already receiving an effective drug therapy. "
"These results - highlights the ISS President Enrico Garaci - dimostrano che valeva la pena di esplorare le potenzialità del vaccino Tat. Il miglioramento dei parametri immunologici nei pazienti vaccinati trattati con terapia antiretrovirale rappresenta una tappa importante, e non ci fermiamo qui». I passi successivi sono ancora più ambiziosi: valutare l’effetto del vaccino in pazienti sintomatici, per bloccare la malattia, e poi valutare l’effetto preventivo del vaccino, ossia su pazienti sani. «Il meccanismo della Tat è sempre quello - conferma Ensoli - e noi speriamo che il vaccino funzioni anche per le altre indicazioni. Finora abbiamo ottenuto risultati superiori alle nostre aspettative, e molto rapidi».
L’iter di sperimentazione del vaccino Italian treatment started 15 years ago, the clinical phase I started in 2003, Phase II in 2008 and has yet to finish. The problem, however, said Ensoli, time is money: "We no longer have funds to complete Phase II."
beginning of the trial were spent around 20 million euro, against the Ministry of Health and Iss, "but the figure was 20 times higher," highlights Garaci, to test whether the vaccine had been an private rather than public bodies. Now the ISS holds 10 patents which, when it comes to produce the vaccine will also be sold to private companies. "Our goal is to treat patients and we have no foreclosure on transparent partnerships with the private sector, "concludes Ensoli.
SOURCE lastampa.it
0 comments:
Post a Comment